CARsgen Therapeutics Holdings Limited (HKG:2171)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
10.87
-1.09 (-9.11%)
At close: Mar 6, 2026
Market Cap6.04B +15.1%
Revenue (ttm)139.84M +218.7%
Net Income-108.90M
EPS-0.20
Shares Out555.80M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,863,530
Average Volume2,127,028
Open11.96
Previous Close11.96
Day's Range10.87 - 12.14
52-Week Range9.90 - 25.60
Beta0.40
RSI28.19
Earnings DateMar 6, 2026

About HKG:2171

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junct... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 371
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2171
Full Company Profile

Financial Performance

In 2025, HKG:2171's revenue was 125.66 million, an increase of 218.74% compared to the previous year's 39.43 million. Losses were -97.86 million, -87.74% less than in 2024.

Financial numbers in CNY Financial Statements